NEW DELHI – Medium- to large-sized Indian pharmaceutical companies are aggressively pursuing international acquisitions to strengthen their market presence across developed and emerging markets, and to gain a foothold in markets they are currently not strong in, according to new analysis by the Associated Chambers of Commerce and Industry of India (Assocham) and Hyderabad-based Sathguru Management Consultants.
NEW DELHI – With multiple biosimilars introduced and several in the pipeline, India’s biosimilars segment is expected to touch $1.4 billion in 2016, growing at a rate of 30 per year, according to the latest report by an industry association.
NEW DELHI – With multiple biosimilars introduced and several in the pipeline, India's biosimilars segment is expected to touch $1.4 billion in 2016, growing at a rate of 30 per year, according to the latest report by an industry association.
NEW DELHI – Start-ups and spin-offs could boost India’s biopharma sector, as long as the sector as a whole can overcome a series of hurdles, including a chronic shortage of financing.
NEW DELHI – Start-ups and spin-offs could boost India's biopharma sector, as long as the sector as a whole can overcome a series of hurdles, including a chronic shortage of financing.
HYDERABAD, India – Indian companies, backed by the government, are making a strong push to become world-class biosimilar manufacturers. And they might have a shot at that status if they can overcome chronic problems with quality control, limited funding and the fact that making big molecule biologics can be much more difficult than developing and manufacturing the small-molecule generics that long powered the country's pharmaceutical industry.
HYDERABAD, India – Indian companies, backed by the government, are making a strong push to become world-class biosimilar manufacturers. And they might have a shot at that status if they can overcome chronic problems with quality control, limited funding and the fact that making big molecule biologics can be much more difficult than developing and manufacturing the small-molecule generics that long powered the country’s pharmaceutical industry.
HYDERABAD, India – Despite reservations private equity players might have about a sector with longer gestation periods and stringent regulations, India’s biopharmaceutical industry appears to be in an upbeat mood with new investments on the way and at least one state government announcing a land bonanza to set up biotech parks.
